The system is indicated for use in skeletally mature patients with Degenerative Disc Disease at one or two contiguous levels from L2-S1 from a posterior approach for lumbar interbody fusion.
Medyssey Spine claims the LP Cage device addresses the market need for advanced spinal fusion solutions with an indication comprised of two footprints with three varying degrees of lordosis and substantial graft windows for maximum endplate to endplate contact.
Medyssey Spine vice president of Sales for the Americas Joseph Jin said the company’s focus is to have the most complete thoracolumbar systems on the market, which is evidenced by their pipeline of new products currently in regulatory submission and commitment to building out interbody and biologics platforms.
The product is currently in limited, controlled release and is targeted for full commercial launch by Q4 2011.
